Complete Listing of the Claims

This Listing of Claims replaces all prior versions of claims in the Subject Application.

 (Currently amended) A method of controlling expanding a population of human stem cells by promoting self-renewal of [[a]] the population of human-compatible stem cells by reducing intracellular levels of p18 comprising:

delivering small RNA interfering sequences (siRNA) to the human-eempatible stem cells for the reduction of p18 levels in the intracellular environment of the stem cells.

- (Currently amended) The method of claim 1, wherein said <u>human</u> stem cells are predominantly undifferentiated <u>adult</u> stem cells.
- 3-5. (Canceled)
- (Currently amended) The method of claim 1 further comprising implanting the siRNA treated human-compatible stem cells into a human[[;]] wherein the implanted human-stem cells are self-renewing.
- 7. (Currently amended) The method of claim 6, wherein said <u>siRNA treated human</u> stem cells are predeminantly undifferentiated <u>adult</u> stem cells.
- 8-22. (Canceled)

23. (Currently amended) A method of stimulating self-renewal of a population of human-compatible stem cells by reducing intracellular levels of p18 comprising:

delivering small RNA interfering sequences (siRNA) to the human-compatible stem cells by one of electroporation or lentiviral vector for the reduction of p18 levels in the intracellular environment of the stem cells.

- 24. (Currently amended) The method of claim 23, wherein said <u>human</u> stem cells are predominantly undifferentiated adult stem cells.
- 25. (Canceled)
- 26. (Currently amended) The method of claim 23, further comprising implanting the siRNA treated human-compatible stem cells into a human[[;]] wherein the implanted human stem cells are self-renewing.
- 27. (Currently amended) The method of claim 26, wherein said <u>siRNA treated</u> human stem cells are predominantly undifferentiated <u>adult</u> stem cells.
- 28. (Canceled)
- (New) The method of claim 2, wherein said adult stem cells are hematopoietic stem cells.
- 30. (New) The method of claim 2, wherein said adult stem cells are non-hematopoietic stem cells.
- 31. (New) The method of claim 7, wherein said adult stem cells are hematopoietic stem cells.
- 32. (New) The method of claim 7, wherein said adult stem cells are non-hematopoietic stem cells.

- 33. (New) The method of claim 6, wherein the siRNA treated human stem cells contain no intracellular p18.
- 34. (New) The method of claim 24, wherein said adult stem cells are hematopoietic stem cells.
- 35. (New) The method of claim 24, wherein said adult stem cells are non-hematopoietic stem cells.
- 36. (New) The method of claim 27, wherein said adult stem cells are hematopoietic stem cells.
- (New) The method of claim 27, wherein said adult stem cells are nonhematopoietic stem cells.
- 38. (New) The method of claim 26, wherein the siRNA treated human stem cells contain no intracellular p18.
- 39. (New) The method of promoting self-renewal of a population of human stem cells comprising:

expanding the population of human stem cells by delivering small RNA interfering sequences (siRNA) to the human stem cells for a reduction of p18 levels in the intracellular environment of the stem cells.